MS patients less tolerant of risk when it comes to therapies a year later – Examiner

When the study was started, the risk for PML was thought to be 1 in 1,000 without the knowledge of the combination of three things: exposure to the JC virus, previous use of immunosuppressant therapy and how long each patient has been using Tysabri therapy.